Theravance Biopharma (TBPH) Net Cash Flow (2014 - 2026)

Theravance Biopharma (TBPH) has 13 years of Net Cash Flow data on file, last reported at $120.3 million in Q1 2026.

• On a quarterly basis, Net Cash Flow rose 65.2% year-over-year to $120.3 million in Q1 2026; TTM through Mar 2026 was $177.5 million, a 212.59% increase from a year earlier, with the FY2025 full-year figure at $130.0 million, up 7537.59% from the prior year.
• Net Cash Flow for Q1 2026 stood at $120.3 million, up from -$7.0 million in the prior quarter.
• Over the last five years, Net Cash Flow for TBPH reached as high as $171.3 million in Q2 2025 and fell as low as -$758.3 million in Q3 2022.
• Historically, Net Cash Flow has averaged -$40.7 million across 5 years, with a median of -$7.1 million in 2022.
• Across the five-year window, Net Cash Flow tumbled 2607.53% in 2023 and surged 2387.22% in 2025, its largest moves.
• Year by year, Net Cash Flow stood at $78.8 million in 2022, then slumped by 140.79% to -$32.1 million in 2023, then soared by 144.86% to $14.4 million in 2024, then tumbled by 148.32% to -$7.0 million in 2025, then jumped by 1826.64% to $120.3 million in 2026.
• Per Business Quant data, the three most recent Net Cash Flow figures were $120.3 million in Q1 2026, -$7.0 million in Q4 2025, and -$107.2 million in Q3 2025.